After the coronavirus crisis is over, Europe will need policies that can create a research ecosystem in the long run as well as ensure access to medicines to the patients who need them in a way that is sustainable for health systems today and tomorrow, a top European pharmaceutical official told EURACTIV in an interview.
“We believe that by working together and sitting around the table, post-COVID, Europe can achieve both of these ambitions,” said Nathalie Moll, the director-general of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Read more
European Centre for Clinical Research Training (ECCRT), has been selected as a premium provider for continuous online...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.